Growth Metrics

Pharming Group N.V (PHAR) Cost of Revenue: 2020-2025

Historic Cost of Revenue for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to $7.1 million.

  • Pharming Group N.V's Cost of Revenue rose 3.70% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.4 million, marking a year-over-year increase of 12.17%. This contributed to the annual value of $35.4 million for FY2024, which is 40.41% up from last year.
  • According to the latest figures from Q3 2025, Pharming Group N.V's Cost of Revenue is $7.1 million, which was down 59.12% from $17.3 million recorded in Q2 2025.
  • Pharming Group N.V's 5-year Cost of Revenue high stood at $21.1 million for Q4 2021, and its period low was -$9.5 million during Q3 2021.
  • Moreover, its 3-year median value for Cost of Revenue was $8.3 million (2023), whereas its average is $9.7 million.
  • In the last 5 years, Pharming Group N.V's Cost of Revenue plummeted by 266.72% in 2021 and then spiked by 100,602.04% in 2022.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Cost of Revenue stood at $21.1 million in 2021, then tumbled by 70.30% to $6.3 million in 2022, then climbed by 13.45% to $7.1 million in 2023, then skyrocketed by 71.58% to $12.2 million in 2024, then climbed by 3.70% to $7.1 million in 2025.
  • Its Cost of Revenue stands at $7.1 million for Q3 2025, versus $17.3 million for Q2 2025 and $12.2 million for Q4 2024.